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Chronic disseminated candidiasis is a complication of the intensive therapies of hematological malignancies 
revealed during hematopoietic recovery, a context reminiscent of the immune restoration inflammatory 
syndrome in human immunodeficiency virus patients receiving antiretroviral therapy. We report a case of 
severe exacerbation of chronic disseminated candidiasis after pegylated granulocyte-colony stimulating 
factor administration. We emphasize the major inflammatory substrate of the disease and suggest 
that immune-modulating strategies such as hematopoietic growth factors, should be used cautiously
in such patients.
KEYWORDS:  chronic disseminated candidiasis, hematopoietic growth factors, hepatosplenic candidiasis, 
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Introduction
Bodey et al first described hepatosplenic candidiasis, also 
referred as chronic disseminated candidiasis (CDC), in 
1969.1 It since has been recognized as a complication of 
the intensive therapies used in hematological malignan-
cies, occurring in about 5% of acute myeloid leukemia 
(AML) cases.2
The pathophysiology of CDC is not yet fully under-
stood. It is hypothesized that an initial colonization of 
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the gastrointestinal tract by Candida species, followed 
by blood translocation through the portal venous system, 
induces fungal hepatic and splenic dissemination. Large 
probabilistic antifungal therapy, justified by the aplasia-
induced high dose chemotherapy, prevents the onset of a 
clinically apparent invasive fungal infection (IFI). CDC is 
then only revealed in the course of neutrophil recovery 
with fever, liver pain, cholestasis, disturbance of inflam-
matory parameters and disseminated hepatic and splenic 
abscess-like nodular lesions.3 A major characteristic is 
the absence of evidence for an active IFI as judged by the 
absence of Candida sp. growth on liver biopsy specimens, 
blood or elsewhere. In contrast, non-specific inflammatory 
lesions, most usually a typical granulomatous reaction, 
are revealed.4,5 Thus, CDC appears to share several features 
with IFI-associated immune reconstitution inflammatory 
syndrome (IRIS) also described in newly treated human 
immunodeficiency virus (HIV)-infected patients, or solid 
organ-transplanted patients.4,6
Until now, CDC was reported to require long-term 
systemic antifungal therapy. However, some cases of per-
sisting, relapsing or even life-threatening manifestations, 
unresponsive to antifungals, have been reported, severely 
alleviating the prognosis.2 In such patients, steroids may 
represent a useful adjuvant therapeutic procedure.5
We report a case of severe exacerbation of CDC follow-
ing the use of pegylated granulocyte-colony stimulating 
factor (G-CSF), as confirmed by a significant worsening of 
hepatic lesions with extensive granulomas and necrosis. 
We discuss the potential promoting impact of hematopoi-
etic growth factors in the development and severity of CDC 
and also illustrate the beneficial impact of corticosteroids 
(CST) in severe forms of CDC.
Case Report
In November 2006, a 75-year-old man was diagnosed with 
AML M0 with normal cytogenetics. Chronic lymphocytic 
leukemia Binet stage A had been diagnosed 10 years prior 
to AML, not necessitating any treatment. He received 
induction chemotherapy for AML with intravenous ida-
rubicin (9 mg/m2/day) for 4 days + cytosine arabinoside 
(200 mg/m2/day) continuously for 7 days, supported with 
a single injection of pegylated G-CSF (pegfilgrastim, 6 mg 
on day 9). During the neutropenic period, and after first 
receiving conventional broad-spectrum antimicrobial ther-
apy and empirical caspofungin for persistent fever, he was 
diagnosed with a possible pulmonary aspergillosis (Day 
20 post-chemotherapy). He was then switched to voricona-
zole, 200 mg twice daily, with serum residual therapeutic 
levels > 1 ng/mL.
As neutrophil recovery occurred (December 16, 2006 
on Day 24 post-chemotherapy), the patient was again 
febrile. Complete remission was documented on bone mar-
row examination. Computed tomography scanning showed 
regression of the suspected aspergillosis-related pulmo-
nary nodules but the presence of multiple abscess-like 
liver and spleen lesions consistent with CDC (Figure 1A). 
At that time, screening for infectious agents, including 
Mycobacteria, was unsuccessful. Tests for Candida sp. car-
riage (urine, stools, blood, and mouth) as well as anti-
Candida antibodies and serum mannan antigenemia 
detection were negative. Histological analysis of a liver le-
sion biopsy specimen revealed a nonspecific inflamma-
tory infiltrate and fibrosis of portal spaces with no 
infectious agent (PAS or periodic acid Schiff was used 
to detect carbo hydrate containing structures, including 
some fungi, Actinomyces sp. and macrophage inclusions of 
Wipple disease; the Grocott stain was used to detect fun-
gal elements, and the Ziehl-Nielsen stain was used to de-
tect bacteria, notably Mycobacteria) as well as bacterial and 
fungal cultures. There was no underlying metabolic or 
viral hepatic disease. Voriconazole alone was maintained, 
since the fever decreased spontaneously and the patient 
could go on chemotherapy.
In February 2007, after receiving another pegylated 
G-CSF injection (pegfilgrastim, 6 mg) following his first 
consolidation chemotherapy (Idarubicin 9 mg/m2/day on 
day 1 + cytosine arabinoside 100 mg/m2 subcutaneously 
twice per day for 5 days), he was hospitalized with severe 
asthenia, high fever (40°C) and shivers despite a normal 
neutrophil count (6.6 × 109/L) and empirical oral antimi-
crobial therapy of more than 48 hours. No specific infection 
(e.g. Mycobacteria and Bartonella henselae) was documented 
but abdominal ultrasound and computed tomography 
scan revealed a significant worsening of hepatosplenic le-
sions (Figure 1B). Histological findings were significantly 
modified, consisting of typical granulomatous lesions 
surrounding a necrotic center and a peripheral inflamma-
tory reaction associated with the same pre-existing fibrotic 
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lesions. Once again, there was no detectable infectious 
agent on the liver biopsy specimen after specific staining, 
fungal culture and immunohistochemical analysis for 
Candida (streptavidine peroxydase, Biogenesis, Argene). 
A molecular analysis towards bacteriological agents (16S 
rDNA PCR) was also negative. At that time, while main-
taining the same antifungal therapy, we decided upon an 
adjuvant CST therapy due to the severity of the clinical 
manifestations. The patient initially received 0.5 mg/kg/day 
with a rapid tapering over 3 weeks. However, after an ini-
tial improvement, he relapsed while the CST was being 
decreased; CST had to be increased again to 1 mg/kg/day 
and maintained for 1 month. After this, the CST was slowly 
decreased according to clinical symptoms (fever, asthenia, 
abdominal pains) and serum levels of liver enzymes (alka-
line phosphatase and γGT, which were 4 and 8 times the 
normal values, respectively, at CST initiation; Figure 2). 
It is worth noting here that the patient undertook his 
chemotherapy program concomitantly with approxi-
mately monthly consolidation courses (total of 6 identi-
cal courses), but G-CSF was not re-administered due to 
the complications associated with this patient.
Despite CST and chemotherapy, the patient did not suf-
fer any other serious infectious complications. In October 
2007, CST and voriconazole were withdrawn, based on 
the normalization of inflammatory (C-reactive protein 
and fibrinogen) and liver parameters, (except γGT, which 
was 1.5 times higher than the normal value, possibly owing 
to voriconazole-related toxicity; Figure 2). The hepatic 
and splenic lesions had been replaced by non-evolving 
sequelae. After 18 months, the patient showed no signs of 
relapse of either hematological or inflammatory disease.
Discussion
CDC is a well-recognized entity corresponding to an inflam-
matory complication of systemic infections by Candida sp., 
mostly of the liver, spleen and, more rarely, the lung and 
the kidneys. It can arise during the course of hematopoi-
etic recovery after intensive chemotherapy.2,3 However, 
the pathophysiology of CDC is unclear and the manage-
ment of patients with CDC in current clinical practice is 
still challenging. The original nature of the case presented 
here led to a reliance on the identification of a potentially 
very strong immune risk factor predisposing to severe 
forms of CDC, i.e. the use of hematopoietic growth factors.
Evolving Candida sp.-related invasive infections are 
preferentially associated with an unbalanced Th2-type 
immune response.7,8 This is deleterious, since an effective 
response against Candida sp. infections requires a Th1-
type immune response, with a major role for TNF-α (tumor 
necrosis factor-alpha) and IFN-γ (interferon-gamma) 
production.9,10 In contrast, CDC is thought to result from 
an excessive Th1 response,5 as testified by the presence of 
necrotizing granulomas and T cell-type lymphoid infil-
trates, and the absence of fungal documentation, apart 
from potential debris from dead fungi. This last implies 
that the pre-existing Candida sp.-related IFI is perfectly 
well-controlled at the time of CDC diagnosis. Finally, the 
onset of the disease during hematopoietic restoration fol-
lowing intensive chemotherapy is also a major criterion in 
favor of an excessive immune reaction and justifies the in-
clusion of CDC within the spectrum of IFI-related immune 
restoration inflammatory syndrome, a disease typically 
mediated through an uncontrolled Th1-type immune 
Figure 1. (A) Computed tomography scan showing exacerbation of hepatosplenic lesions. (B) Liver biobsy specimen recealing a typical 
epithelioid reaction surrounding a necrotic center.
A B
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response and observed in various pathological conditions, 
including patients infected with HIV and/or Mycobacterium 
tuberculosis, or solid organ transplant recipients.6,11 At 
present, however, specific studies are needed to precisely 
identify the immune substrate of CDC and to demon-
strate the hypothesis of an excessive Th1 immune reaction 
described elsewhere for standard cases of IRIS.4,11
Filgrastim is a recombinant human G-CSF, which accel-
erates neutrophil recovery after hematotoxic chemotherapy 
and/or stimulates peripheral blood stem cell mobiliza-
tion to prepare for autologous stem cell transplantation 
following high-dose chemotherapy. The pegylated form 
of filgrastim exhibits a major hematopoietic growth factor 
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Figure 2. Biological parameters evolution according to pegylated G-CSF and corticosteroid therapy. PMN = Polymorphonuclears; 
ALP = alkaline phosphatases; CRP = C-reactive protien; GGT = gamma glutamyl transferase.
Years 2006 2007 Normal 
rangeDay/month 16/11 19/12 21/01 04/03 20/03 04/04 20/05 29/06 16/08
PMN 0.6 7.7 7.2 24.0 10.6 6.6 11.4 7.5 3.9 2–7.5 × 109/L
CRP 12 137 240 146 86 61 12 24 < 10 mg/L
ALP 88 166 561 516 622 376 421 200 210 < 135 IU/L
GGT 14 130 133 405 413 231 139 151 147 < 50 IU/L
Fibrinogen 6.8 7 7 3.4 3–4 g/L
activity in vivo because of a prolonged half-life owing to a 
reduction in renal clearance. Pegfilgrastim is associated 
with earlier, and stronger, neutrophil recovery compared 
with filgrastim, as demonstrated by higher CD34 progeni-
tor levels after hematotoxic chemotherapy, and its success-
ful use for peripheral blood stem cell mobilization rescue 
in poor mobilizer patients with multiple myeloma.12,13
Filgrastim primarily affects neutrophil progenitors 
and its effects on other immune cells appear either lim-
ited or contradictory. However, G-CSF therapy probably 
has immune-modulating properties for monocytes/macro-
phages, i.e. Th1/2 lymphocyte-inducing dendritic cells,14,15 
and it apparently has the potential to induce disparate 
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immune responses depending on the underlying disease 
and/or the context.16,17
Little is known about the impact of G-CSF use on neu-
tropenic patients treated for a Candida sp. invasive infec-
tion following hematotoxic chemotherapy. In a mouse 
model of disseminated candidiasis, Graybill et al18 re-
ported that mice treated with G-CSF and fluconazole 
showed increased survival and a reduced kidney tissue 
count of Candida sp. compared with mice receiving fluco-
nazole or G-CSF alone. There are currently no human 
data available, either after recovery from neutropenia or 
in the context of CDC. Based on the pathophysiology 
of IFI-related IRIS in HIV-infected patients4,6,11 and the 
consistency of a Th1-type immune response in CDC, it 
is tempting to postulate that CDC may be exacerbated 
through G-CSF therapy itself (i.e. increased immune cell 
recruitment at the abscesses sites) as well as through the 
promotion of an additive and potent Th1 immune re-
sponse. Therefore, G-CSF, and particularly its long half-
life pegylated form, should be used cautiously in recovering 
leukemic patients who have suffered, or are still suffering 
from an IFI, especially in a proven case of CDC.
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